Astellas Pharma, Inc.

The Voya Japan TOPIX Index Portfolio fell by 6.7% in September 2015 from the previous month.

The Nuveen Tradewinds Japan Fund – A (NTJAX) fell 4.4% in August from a month ago. In the three-month period ended August 31, it fell 2.1%, the third least faller.

Yesterday, Scynexis (SCYX) stock rose 16.4% on the announcement of positive data from its Phase 2b clinical trial of SCY-078.

Merck & Company’s (MRK) Bridion generated revenue of $204 million in Q1 2018 compared to $148 million in Q1 2017.

In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter.

Apart from Roxadustat, other products in FibroGen’s pipeline include Pamrevlumab (or FG-3019) and FG-5200.

In 4Q17, Novartis’s Immunology and Dermatology segment generated revenues of $1.2 billion, ~30% growth on a year-over-year (or YoY) basis and ~9% growth quarter-over-quarter.

In 4Q17, Merck’s (MRK) Invanz generated revenues of $157 million, which represents a ~3% rise on a YoY (year-over-year) basis.

In 3Q17, Valeant’s (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.

In 3Q17, Johnson & Johnson’s (JNJ) Zytiga generated revenues of $669 million, which reflected ~15% growth on a year-over-year (or YoY) basis and 20% growth on a quarter-over-quarter basis.

Since its launch, Synergy’s (SGYP) Trulance sales have been steadily rising. In 3Q17, more than 25,000 prescriptions were filled for the drug.

In 3Q17, Novartis’s (NVS) Neoral generated revenues of ~$126 million, which represents a ~3% YoY (year-over-year) fall and a 2% QoQ fall.

In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million.

The Fidelity Advisor Overseas Fund – Class A (FAOAX) has emerged as a below-average performer in YTD 2016 among the 12 funds chosen for this review.

The Fidelity Advisor Overseas Fund invests at least 80% of its net assets in common stocks of non-US issuers.

TGRAX is quite balanced as far as allocation in its top three sectors is concerned.

Financials have contributed the lion’s share of the BlackRock Pacific Fund – Investor A Shares’ (MDPCX) poor showing in 2016 YTD.

The Fidelity Advisor Overseas Fund’s (FAOAX) top sectoral bet is the consumer discretionary sector, which forms one-fourth of the fund’s total assets.

Financials were the biggest negative contributors to CNJFX’s total returns in the first four months of 2016.

Medivation (MDVN) earned collaboration revenue from Xtandi’s US and non-US sales along with upfront and milestone payments.

The NHI revises drug prices every two years. During fiscal 2016, a 6.8% reduction in drug prices is expected.

The drug approval process in Japan includes a sequence of non-clinical studies, clinical studies followed by approval review, and post-marketing surveillance.

The Fidelity Advisor Overseas Fund – Class A (FAOAX) was incepted in September 1996 and has an expense ratio of 1.4%.

The T. Rowe Price International Stock Fund (PRITX) has been in existence since May 1980.

The Invesco Pacific Growth Fund, under normal circumstances, will invest “at least 80% of its net assets in securities of issuers in the Pacific region.”

The Columbia Pacific/Asia Fund (CASAX) aims to invest 80% of its net assets in equity securities of companies “located in Asia and the Pacific Basin.

The T. Rowe Price Japan Fund (PRJPX) is well diversified with 78 holdings as of December 2015. It was managing assets worth $330.08 million at the end of December.

The Fidelity Japan Fund’s (FJPNX) assets were spread across 86 securities as of December 2015 and it was managing $545.18 million in assets.

Observing the changes in Pfizer’s stock price after Xalkori’s label update by the European Commission shows that the stock price rose by ~2.8%.

Pfizer’s oncology drug Xalkori, also termed Crizotinib, was approved for label expansion and label update by the European Commission on November 25.

Profile 1014 is the Phase III study for Xalkori, an ALK inhibitor. As per Pfizer’s press release, study was a randomized, and involved 343 patients.

The Voya Japan TOPIX Index Portfolio Class A is an index fund, not an actively managed mutual fund, so it necessarily tracks its benchmark index.

The Fidelity Japan Fund invests at least 80% of its assets in securities of Japanese issuers and other investments that are tied economically to Japan.